JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

145.91

-0.57%↓

Home・Akcijų sąrašas・Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

12.66 3.26

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

12.07

Max

12.67

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-1.8M 22M
Pardavimai	7.5M 70M
P/E Sektoriaus vid.	27.535 37.461
Pelno marža	30.729
Darbuotojai	130
EBITDA	6.3M 28M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	-1.85% downside

Dividendai
By Dow Jones
Kitas uždarbis	2025-11-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	357M 1.6B
Ankstesnė atidarymo kaina	9.4
Ankstesnė uždarymo kaina	12.66

Naujienos nuotaikos

By Acuity

50%

163 / 373 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

8.1 / 8.21 Palaikymas ir pasipriešinimas

Aurinia Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-27 23:32; UTC

Įsigijimai, susijungimai, perėmimai

CSL Delays Flu-Vaccine Spinoff, Cuts Guidance As U.S. Vaccination Rates Decline

2025-10-27 23:00; UTC

Įsigijimai, susijungimai, perėmimai

Australia's AUB Opens Books to EQT After Receiving $3.44 Billion Takeover Offer

2025-10-27 21:42; UTC

Uždarbis

Waste Management 3Q Revenue Climbs, Sees Fiscal Year Revenue at Low End of Prior View

2025-10-27 23:43; UTC

Rinkos pokalbiai

Nikkei May Rise on Easing U.S.-China Trade Tensions -- Market Talk

2025-10-27 23:42; UTC

Rinkos pokalbiai

Gold Rises on Likely Technical Recovery -- Market Talk

2025-10-27 23:37; UTC

Rinkos pokalbiai

Investors May Cheer CSL's Decision to Delay Seqirus Spinoff -- Market Talk

2025-10-27 23:00; UTC

Uždarbis

The Good Vibes Are Back on Wall Street -- WSJ

2025-10-27 22:45; UTC

Įsigijimai, susijungimai, perėmimai

Australia's AUB Opens Books to EQT After Receiving $3.44B Takeover Offer

2025-10-27 22:06; UTC

Rinkos pokalbiai

Uždarbis

Nucor Expects Weaker Steel Market in 4Q -- Market Talk

2025-10-27 22:05; UTC

Uždarbis

China Southern Airlines: Continued Improvements in Business Environment Supported Results >1055.HK

2025-10-27 22:04; UTC

Uždarbis

Cadence Reports Solid Earnings. The Stock Is Falling. -- Barrons.com

2025-10-27 22:04; UTC

Uždarbis

China Southern Airlines 3Q Net CNY3.84B, Up 20.3% on Year >1055.HK

2025-10-27 22:03; UTC

Uždarbis

China Southern Airlines 3Q Rev CNY51.37B, Up 3.0% on Year >1055.HK

2025-10-27 21:27; UTC

Uždarbis

Waste Management 3Q Rev Climbs, Sees FY Rev at Low End of Prior View

2025-10-27 21:19; UTC

Uždarbis

Cadence Reports Solid Earnings. The Stock Is Falling. -- Barrons.com

2025-10-27 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Health Care Roundup: Market Talk

2025-10-27 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-27 20:37; UTC

Uždarbis

Waste Management: Decrease From Prior Rev Expectations Is Primarily Related to Further Decline in Recycled Commodity Pricing, Modestly Lower Rev Expectations From Healthcare Solutions >WM

2025-10-27 20:37; UTC

Uždarbis

Waste Management: 2025 Free Cash Flow Guidance Remains Between $2.8B and $2.9B >WM

2025-10-27 20:37; UTC

Uždarbis

Waste Management: 2025 Total Co Rev Is Now Expected Approximately $25.275B >WM

2025-10-27 20:37; UTC

Uždarbis

Waste Management: Affirming 2025 Adjusted Operating EBITDA Guidance Between $7.475B and $7.625B >WM

2025-10-27 20:31; UTC

Uždarbis

Nucor Sees 4Q Earnings Lower Than 3Q

2025-10-27 20:30; UTC

Uždarbis

Nucor 3Q Steel Mills Total Shipments 6.43M Tons >NUE

2025-10-27 20:30; UTC

Uždarbis

Nucor 3Q EPS $2.63 >NUE

2025-10-27 20:30; UTC

Uždarbis

Nucor 3Q Net $607M >NUE

2025-10-27 20:30; UTC

Uždarbis

Nucor 3Q Sales $8.52B >NUE

2025-10-27 20:30; UTC

Uždarbis

Nucor 3Q Total Tons Shipped to Outside Customers Down 1% >NUE

2025-10-27 20:30; UTC

Uždarbis

Waste Management 3Q Adj EPS $1.98 >WM

2025-10-27 20:30; UTC

Uždarbis

Waste Management 3Q Rev $6.44B >WM

2025-10-27 20:30; UTC

Uždarbis

Waste Management 3Q Net $603M >WM

Akcijų palyginimas

Kainos pokytis

Aurinia Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

-1.85% į apačią

12 mėnesių prognozė

Vidutinis 11.67 USD -1.85%

Aukščiausias 17 USD

Žemiausias 9 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Aurinia Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

Pirkti

Laikyti

Parduoti

Remiantis 6 analitikų, pateikusių Aurinia Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

8.1 / 8.21Palaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There is one bullish event.

Rinkos nuotaikos

By Acuity

163 / 373 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.